0000950123-13-007429 Sample Contracts

OXFORD IMMUNOTEC, INC. LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • North Carolina

This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of May 24, 2013, by and between Square 1 Bank (“Bank”) and Oxford Immunotec, Inc. (“Borrower”).

Sample 1Sample 2Sample 3See All (52)
AutoNDA by SimpleDocs
Dated 8 August 2007 MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED and OXFORD IMMUNOTEC LIMITED Counterpart LEASE of Unit 94C Milton Park
Oxford Immunotec Global PLC • September 10th, 2013 • In vitro & in vivo diagnostic substances
Sample 1Sample 2Sample 3See All (9)
OFFICE LEASE AGREEMENT BETWEEN NORMANDY NICKERSON ROAD, LLC (“LANDLORD”) AND OXFORD IMMUNOTEC, INC. (“TENANT”)
Office Lease Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

telecommunications and furniture and equipment. The Allowance, less a 10% retainage (which retainage shall be payable as part of the final draw upon completion of the Initial Alterations), shall be paid to Tenant or, at Landlord’s option, to the order of the general contractor that performs the Initial Alterations, in periodic disbursements within 30 days after receipt of the following documentation: (i) an application for payment and sworn statement of contractor substantially in the form of AIA Document G-702 covering all work for which disbursement is to be made to a date specified therein; (ii) a certification from an AIA architect substantially in the form of the Architect’s Certificate for Payment which is located on AIA Document G702, Application and Certificate of Payment; (iii) Contractor’s, subcontractor’s and material supplier’s waivers of liens which shall cover all Initial Alterations for which disbursement is being requested and all other statements and forms required for

Sample 1Sample 2Sample 3
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. StemCell Technologies, Inc. - and – Oxford...
Supply Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • British Columbia

THIS AGREEMENT dated as of 31st January, 2008 between OXFORD IMMUNOTEC LTD., a corporation incorporated under the laws of the United Kingdom having its principal place of business in Abingdon, Oxfordshire, United Kingdom (“Oxford”) and STEMCELL TECHNOLOGIES, INC., a corporation incorporated under the laws of British Columbia and Canada having its principal place of business in Vancouver, British Columbia, Canada (“StemCell”).

Sample 1Sample 2Sample 3
Dated 21st October 2002 OXFORD IMMUNOTEC LIMITED (1) and DR P WRIGHTON-SMITH (2) SERVICE AGREEMENT
Service Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Sample 1Sample 2Sample 3
OXFORD IMMUNOTEC LIMITED NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR NON-CALIFORNIA OPTION HOLDERS
Nonstatutory Stock Option Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • California

OXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and

Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Letter of Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

Oxford lmmunotec Limited (“OI”), a company registered in England (number 4516079), whose registered office is at 3 Worcester Street, Oxford, OX1 2PZ.

Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SUPPLY AND RESELLER AGREEMENT
Supply and Reseller Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York

This Supply and Reseller Agreement (the “AGREEMENT”) is by and between LIFE TECHNOLOGIES CORPORATION (“LTC”), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. (“OI”), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, U.K., and is effective as of August 12, 2013 (the “EFFECTIVE DATE”).

Sample 1Sample 2
Contract
Amendment • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

This Amendment (the “Second Amendment”) is made as of May 24th, 2011 by and between Mabtech AB, whose registered office is at Augustendalsvägen 19, SE-131 28, Nacka Strand, Sweden, hereinafter referred to as “Seller” or “Mabtech” and Oxford lmmunotec Limited, whose registered office is at 94C Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK, hereinafter referred to as “Buyer” or “OI”.

Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT
Oxford Immunotec Global PLC • September 10th, 2013 • In vitro & in vivo diagnostic substances

This amendment (the “Amendment”) is entered into and effective as of 22nd December 2011 to a Distributorship Agreement (the “Original Agreement”) dated 5 June 2009 by and among Oxford Immunotec Limited, an English company having offices at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, Shanghai Fosun Long March Medical Science Co. Ltd., whose registered office and principal place of business is both at 995 Xiang Yin Road, Shanghai, China 200433 and Shanghai Xin Chang Medical Device Co. Ltd., whose registered office is at Room 214, Suite 1, 1128 Ping Liang Road, Shanghai, China 200433.

Sample 1Sample 2
STANDARD COMMERCIAL LEASE
Lease Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED AMENDMENT TO SUPPLY AGREEMENT
Supply Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

This amended and restated amendment (the “Amendment”) is made and effective as of October 26, 2011 by and between STEMCELL Technologies, having a place of business at 570 West 7th Avenue, Suite 400, Vancouver, British Columbia, Canada, V5Z 1B3 and Oxford Immunotec Ltd., having its principal place of business at 94C Milton Park Abingdon, Oxfordshire, United Kingdom, OX14 4RY.

Sample 1Sample 2
OXFORD IMMUNOTEC LIMITED INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR NON-CALIFORNIA OPTION HOLDERS
Incentive Stock Option Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • California

OXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and

Sample 1Sample 2
OXFORD IMMUNOTEC LIMITED ENTERPRISE MANAGEMENT INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER THE AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR UK QUALIFYING EMPLOYEES
Enterprise Management Incentive Stock Option Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • Oxfordshire

OXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and , an employee of the Company (the “Option Holder”) on , (the “Date of Grant”)

Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated: 5 June 2009 OXFORD IMMUNOTEC LIMITED and...
Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Sample 1Sample 2
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIRST AMENDMENT TO LICENSE AGREEMENT
License Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

This first amendment (“First Amendment”) is entered into and effective as of July 1, 2009, by and between PHRI Properties, Inc., a nonprofit corporation of the State of New Jersey having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI PROPERTIES”) and Oxford Immunotec Limited, an English company having offices at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom (“OXFORD IMMUNOTEC”), collectively “the Parties.”. This First Amendment amends the License Agreement (the “Agreement”) having an effective date of June 30, 2006, by and between The Public Health Research Institute of The City of New York, Inc., a not-for-profit research corporation of the State of New York having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI”), and OXFORD IMMUNOTEC. PHRI PROPERTIES is the assignee of PHRI to its rights and obligations under the Agreement.

Sample 1
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENT
License Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York

This License Agreement (the “Agreement”) is between The Public Health Research Institute of The City of New York, Inc., a not-for-profit research corporation of the State of New York, having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI”), and Oxford Immunotec Limited, a British corporation having offices at 91 Milton Park, Abingdon, Oxon OX14 4RY, United Kingdom (“OXFORD IMMUNOTEC”), collectively “the Parties.”

Sample 1
Contract
Oxford Immunotec Global PLC • September 10th, 2013 • In vitro & in vivo diagnostic substances

This Amendment is made as of January 1, 2010 by and between Mabtech AB, whose registered office is at Augustendalsvägen 19, SE-131 28, Nacka Strand, Sweden, hereinafter referred to as “Seller” or “Mabtech” and Oxford Immunotec Limited, whose registered office is at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY, UK, hereinafter referred to as “Buyer” or “OI”.

Sample 1
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Licence Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Sample 1
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Fourth Amendment to License Agreement
License Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

This fourth amendment (“Fourth Amendment”) is entered into and effective as of April 24, 2013, by and between the University of Medicine and Dentistry of New Jersey, a body corporate and politic of the State of New Jersey having an office at 1 World’s Fair Drive, Somerset, New Jersey 08873, United States (“UMDNJ”) and Oxford Immunotec Limited, an English company having offices at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom (“OXFORD 1MMUNOTEC”), collectively “the Parties.” This Agreement amends and completely restates the License Agreement having an effective date of June 30, 2006, by and between The Public Health Research Institute of The City of New York, Inc., a not-for-profit research corporation of the State of New York having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI”), and OXFORD IMMUNOTEC, as previously amended by a first amendment having an effective date of July 1, 2009, and by a second amendment having an effective date o

Sample 1
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Supply Agreement
Supply Agreement • September 10th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances

This Supply Agreement (“Agreement”) is made and effective as of 17 December 2010 (the “Effective Date”) by and between MicroCoat Biotechnologie GmbH, whose registered office is at Am Neuland 3, 82347, Bernried am Starnberger See, Germany (the “Supplier”) and Oxford Immunotec Limited, whose registered office is at 94C Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK (the “Buyer”).

Sample 1
Contract
Oxford Immunotec Global PLC • September 10th, 2013 • In vitro & in vivo diagnostic substances • California

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

Sample 1
AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.